High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222

International Journal of Oncology

Volumn 48, Issue 3, 2016, Pages 1029-1038

  Brognara, Eleonora ^a   Fabbri, Enrica ^a   Montagner, Giulia ^a   Gasparello, Jessica ^a   Manicardi, Alex ^b   Corradini, Roberto ^b   Bianchi, Nicoletta ^a   Finotti, Alessia ^a   Breveglieri, Giulia ^a   Borgatti, Monica ^a   Lampronti, Ilaria ^a   Milani, Roberta ^a   Dechecchi, Maria Cristina ^c   Cabrini, Giulio ^c   Gambari, Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Delivery; Glioma; MicroRNAs; MiR 221; MiR 222; MiRNA targeting; Peptide nucleic acids

Indexed keywords

MICRORNA 221; MICRORNA 222; PEPTIDE NUCLEIC ACID; TEMOZOLOMIDE; DACARBAZINE; MICRORNA; MIRN221 MICRORNA, HUMAN; MIRN222 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER RESISTANCE; GENE TARGETING; GLIOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOLECULAR INTERACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CELL SURVIVAL; CHEMISTRY; DRUG RESISTANCE; METABOLISM; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE;

APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; MICRORNAS; PEPTIDE NUCLEIC ACIDS; PHENOTYPE; SURFACE PLASMON RESONANCE;

EID: 84959017161     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3308     Document Type: Article

References (50)

1. Nielsen PE, Egholm M, Berg RH and Buchardt O. Sequenceselective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254: 1497-1500, 1991
2. Nielsen PE. Targeting double stranded DNA with peptide nucleic acid (PNA). Curr Med Chem 8: 545-550, 2001
3. Borgatti M, Lampronti I, Romanelli A, Pedone C, Saviano M, Bianchi N, Mischiati C and Gambari R. Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem 278: 7500-7509, 2003
4. Gambari R. Peptide-nucleic acids (PNAs): A tool for the development of gene expression modifiers. Curr Pharm Des 7: 1839-1862, 2001
5. Gambari R. Biological activity and delivery of peptide nucleic acids (PNA)-DNA chimeras for transcription factor decoy (TFD) pharmacotherapy. Curr Med Chem 11: 1253-1263, 2004
6. Nielsen PE. Peptide nucleic acids (PNA) in chemical biology and drug discovery. Chem Biodivers 7: 786-804, 2010
7. Hatamoto M, Ohashi A and Imachi H. Peptide nucleic acids (PNAs) antisense effect to bacterial growth and their application potentiality in biotechnology. Appl Microbiol Biotechnol 86: 397-402, 2010
8. Gambari R, Borgatti M, Bezzerri V, Nicolis E, Lampronti I, Dechecchi MC, Mancini I, Tamanini A and Cabrini G. Decoy oligodeoxyribonucleotides and peptide nucleic acids-DNA chimeras targeting nuclear factor kappa-B: Inhibition of IL-8 gene expression in cystic fibrosis cells infected with Pseudomonas aeruginosa. Biochem Pharmacol 80: 1887-1894, 2010
9. Pandey VN, Upadhyay A and Chaubey B. Prospects for antisense peptide nucleic acid (PNA) therapies for HIV. Expert Opin Biol Ther 9: 975-989, 2009
10. Nielsen PE. Gene targeting and expression modulation by peptide nucleic acids (PNA). Curr Pharm Des 16: 3118-3123, 2010
11. Manicardi A, Fabbri E, Tedeschi T, Sforza S, Bianchi N, Brognara E, Gambari R, Marchelli R and Corradini R. Cellular uptakes, biostabilities and anti-miR-210 activities of chiral arginine-PNAs in leukaemic K562 cells. ChemBioChem 13: 1327-1337, 2012
12. Fabbri E, Manicardi A, Tedeschi T, Sforza S, Bianchi N, Brognara E, Finotti A, Breveglieri G, Borgatti M, Corradini R, et al. Modulation of the biological activity of microRNA-210 with peptide nucleic acids (PNAs). ChemMedChem 6: 2192-2202, 2011
13. Gambari R, Fabbri E, Borgatti M, Lampronti I, Finotti A, Brognara E, Bianchi N, Manicardi A, Marchelli R and Corradini R. Targeting microRNAs involved in human diseases: A novel approach for modification of gene expression and drug development. Biochem Pharmacol 82: 1416-1429, 2011
14. Fabani MM and Gait MJ. miR-122 targeting with LNA/2?-Omethyl oligonucleotide mixmers, peptide nucleic acids (PNA) and PNA-peptide conjugates. RNA 14: 336-346, 2008
15. Fabani MM, Abreu-Goodger C, Williams D, Lyons PA, Torres AG, Smith KG, Enright AJ, Gait MJ and Vigorito E. Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res 38: 4466-4475, 2010
16. Brown PN and Yin H. PNA-based microRNA inhibitors elicit anti-inflammatory effects in microglia cells. Chem Commun (Camb) 49: 4415-4417, 2013
17. Brognara E, Fabbri E, Aimi F, Manicardi A, Bianchi N, Finotti A, Breveglieri G, Borgatti M, Corradini R, Marchelli R, et al. Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells. Int J Oncol 41: 2119-2127, 2012
18. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518: 107-110, 2015
19. He L and Hannon GJ. MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531, 2004
20. Piva R, Spandidos DA and Gambari R. From microRNA functions to microRNA therapeutics: Novel targets and novel drugs in breast cancer research and treatment (Review). Int J Oncol 43: 985-994, 2013
21. Taylor MA and Schiemann WP. Therapeutic opportunities for targeting microRNAs in cancer. Mol Cell Ther 2: 1-13, 2014
22. Song MS and Rossi JJ. The anti-miR21 antagomir, atherapeutic tool for colorectal cancer, has a potential synergistic effect by perturbing an angiogenesis-Associated miR30. Front Genet 4: 301, 2014
23. Nana-Sinkam SP and Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93: 98-104, 2013
24. Hermansen SK and Kristensen BW. MicroRNA biomarkers in glioblastoma. J Neurooncol 114: 13-23, 2013
25. Shu M, Zheng X, Wu S, Lu H, Leng T, Zhu W, Zhou Y, Ou Y, Lin X, Lin Y, et al. Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. Mol Cancer 10: 59, 2011
26. Chan XH, Nama S, Gopal F, Rizk P, Ramasamy S, Sundaram G, Ow GS, Ivshina AV, Tanavde V, Haybaeck J, et al. Targeting glioma stem cells by functional inhibition of a prosurvival oncomiR-138 in malignant gliomas. Cell Reports 2: 591-602, 2012
27. Wagenaar TR, Zabludoff S, Ahn SM, Allerson C, Arlt H, Baffa R, Cao H, Davis S, Garcia-Echeverria C, Gaur R, et al. Anti-miR-21 suppresses hepatocellular carcinoma growth via broad transcriptional network de-regulation. Mol Cancer Res 13: 1009-1021, 2015
28. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW and Weinberg RA. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 28: 341-347, 2010
29. Shah MY and Calin GA. MicroRNAs miR-221 and miR-222: A new level of regulation in aggressive breast cancer. Genome Med 3: 56, 2011
30. Lambertini E, Lolli A, Vezzali F, Penolazzi L, Gambari R and Piva R. Correlation between Slug transcription factor and miR-221 in MDA-MB-231 breast cancer cells. BMC Cancer 12: 445, 2012
31. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA and Farace MG. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. JBiol Chem 282: 23716-23724, 2007
32. Yang J, Zhang JY, Chen J, Xu Y, Song NH and Yin CJ. Prognostic role of microRNA-221 in various human malignant neoplasms: A meta-Analysis of 20 related studies. PLoS One 9: e87606, 2014
33. Li W, Guo F, Wang P, Hong S and Zhang C. miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. Curr Mol Med 14: 185-195, 2014
34. Chen L, Zhang J, Han L, Zhang A, Zhang C, Zheng Y, Jiang T, Pu P, Jiang C and Kang C. Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. Oncol Rep 27: 854-860, 2012
35. Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han L, Jia ZF, Yang WD, Wang GX, Jiang T, You YP, et al. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 9: 229, 2010
36. Brognara E, Fabbri E, Bazzoli E, Montagner G, Ghimenton C, Eccher A, Cantù C, Manicardi A, Bianchi N, Finotti A, et al. Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221. JNeurooncol 118: 19-28, 2014
37. Jensen KK, Orum H, Nielsen PE and Nordén B. Kinetics for hybridization of peptide nucleic acids (PNA) with DNA and RNA studied with the BIAcore technique. Biochemistry 36: 5072-5077, 1997
38. Corradini R, Feriotto G, Sforza S, Marchelli R and Gambari R. Enhanced recognition of cystic fibrosis W1282X DNA point mutation by chiral peptide nucleic acid probes by a surface plasmon resonance biosensor. J Mol Recognit 17: 76-84, 2004
39. Cao X, Gu Y, Jiang L, Wang Y, Liu F, Xu Y, Deng J, Nan Y, Zhang L, Ye J, et al A new approach to screening cancer stem cells from the U251 human glioma cell line based on cell growth state. Oncol Rep 29: 1013-1018, 2013
40. Abdullah Thani NA, Sallis B, Nuttall R, Schubert FR, Ahsan M, Davies D, Purewal S, Cooper A and Rooprai HK. Induction of apoptosis and reduction of MMP gene expression in the U373 cell line by polyphenolics in Aronia melanocarpa and by curcumin. Oncol Rep 28: 1435-1442, 2012
41. Pen A, Durocher Y, Slinn J, Rukhlova M, Charlebois C, Stanimirovic DB and Moreno MJ. Insulin-like growth factor binding protein 7 exhibits tumor suppressive and vessel stabilization properties in U87MG and T98G glioblastoma cell lines. Cancer Biol Ther 12: 634-646, 2011
42. Rothbard JB, Kreider E, VanDeusen CL, Wright L, Wylie BL and Wender PA. Arginine-rich molecular transporters for drug delivery: Role of backbone spacing in cellular uptake. J Med Chem 45: 3612-3618, 2002
43. Abes R, Arzumanov A, Moulton H, Abes S, Ivanova G, Gait MJ, Iversen P and Lebleu B. Arginine-rich cell penetrating peptides: Design, structure-Activity and applications to alter pre-mRNA splicing by steric-block oligonucleotides. J Pept Sci 14: 455-460, 2008
44. Bhatia B. On the move: p27Kip1 drives cell motility in glioma cells. Cell Cycle 9: 1231-1240, 2010
45. Lu X, Zhao P, Zhang C, Fu Z, Chen Y, Lu A, Liu N, You Y, Pu P and Kang C. Analysis of miR-221 and p27 expression in human gliomas. Mol Med Rep 2: 651-656, 2009
46. Gillies JK and Lorimer IA. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 6: 2005-2009, 2007
47. Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze MT, et al. Dicerregulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci USA 106: 10746-10751, 2009
48. Zerrouqi A, Pyrzynska B, Febbraio M, Brat DJ and Van Meir EG. P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3. JClin Invest 122: 1283-1295, 2012
49. Wang Y, Wang X, Zhang J, Sun G, Luo H, Kang C, Pu P, Jiang T, Liu N and You Y. MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas. J Neurooncol 106: 217-224, 2012
50. Bertucci A, Lülf H, Septiadi D, Manicardi A, Corradini R and De Cola L. Intracellular delivery of peptide nucleic acid and organic molecules using zeolite-L nanocrystals. Adv Healthcare Mater 3: 1812-1817, 2014